FDA Urged to Bar Psoriasis Drug

A federal panel of dermatologists has asked the FDA to avoid approving Tazoral (Allergan), a medication for treating moderate-to-severe psoriasis because of concerns about birth defects and weakened bones. discount drugs canda

The drug’s active ingredient, tazarotene, is available as a gel and a cream. The FDA will be considering the panel’s vote when it decides whether to allow the tablet form of the drug in the U.S.